Measuring Biomarkers in Various Biological Compartments after TBI
Measuring Biomarkers in Various Biological Compartments after TBI
批准号:
8821954
负责人:
Denes V. Agoston
金额:
$7.8万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-01 至 2016-08-31
关键词:
AddressAffectAmericanAntibodiesBiologicalBiological AssayBiological MarkersBloodBlood specimenBrainCaringCause of DeathCerebrospinal FluidCerebrumChronicClassificationClinicalClinical DataClinical ResearchDataDiagnosisDiagnosticDirect CostsEarly DiagnosisEvidence based treatmentExtracellular FluidFacilities and Administrative CostsGlial Fibrillary Acidic ProteinHumanIncomeInjuryLiquid substanceMeasuresMedicalMetabolicMicrodialysisNeurogliaNeuron-Specific EnolaseNeuronsOutcomePathologyPatientsPatternPhaseProcessProductivityProtein Microarray AssayProteinsProteomeProteomicsRehabilitation therapyResolutionSamplingSerumSeveritiesSpecificitySurvivorsSwedenTechniquesTechnologyTestingTimeTraumatic Brain InjuryUniversity HospitalsWorkcostdesigndisabilityevidence baseimprovedinnovationinsightminimally invasiveoutcome forecastpublic health relevanceresearch studytau Proteins
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Traumatic brain injury (TBI) is a major cause of death and chronic disability in the US. The combinations of direct medical expense (~60 BILLION USD annually!), lost income and long-term support are staggering. Early diagnosis and evidence-based treatments are critical to improve outcome after TBI reducing direct and indirect costs and importantly human suffering. This proposal addresses the issue of improving early diagnosis through proteomics analysis of brain microdialysates, CSF and blood samples in relation to clinical data and long-term outcome. Cerebral microdialysis (cMD) is a minimally invasive technique that samples the brain extracellular fluid (bECF) and provides vital information about ongoing metabolic changes in TBI in neurointensive units. Changes in the serum and/or CSF levels of protein biomarkers can be easily determined and can indicate specific pathological changes triggered by the injury. The exact relationship between changes in protein biomarkers in the different biological compartments are currently unknown. As part of an ongoing collaborative effort with the Karolinska University Hospital, Stockholm, Sweden we have collected bECF, CSF and blood samples at every 6 to 12 hrs from 17 TBI patients up to 7 days post- injury. The objective of this proposal is to identify and compare the pattern of changes of neuron and glia specific biomarkers through proteomics analysis among the three bio fluids. Our rationale is that if we establish the relationship between the injury-induced changes in protein biomarkers in the bECF, CSF and serum, we can improve the diagnostic value of changes measured in CSF and serum.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Markers of Cerebrovascular Pathologies in Alzheimer's Disease and Related Dementias
-
批准号:10806855
-
项目类别:
-
资助金额:$68.44万
-
财政年份:2023
-
负责人:Denes V. Agoston
-
依托单位:
Translational Platform for Epilepsy Therapy and Biomarker Discovery
-
批准号:10711486
-
项目类别:
-
资助金额:$1.62万
-
财政年份:2022
-
负责人:Denes V. Agoston
-
依托单位:
Translational platform for epilepsy therapy and biomarker discovery
-
批准号:10467726
-
项目类别:
-
资助金额:$222.91万
-
财政年份:2022
-
负责人:Denes V. Agoston
-
依托单位:
Translational Platform for Epilepsy Therapy and Biomarker Discovery
-
批准号:10605283
-
项目类别:
-
资助金额:$212.24万
-
财政年份:2022
-
负责人:Denes V. Agoston
-
依托单位:
Measuring Biomarkers in Various Biological Compartments after TBI
-
批准号:8914702
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2014
-
负责人:Denes V. Agoston
-
依托单位:
Lymphoid Transcription Factor in Striatal Development
-
批准号:6536167
-
项目类别:
-
资助金额:$7.41万
-
财政年份:2001
-
负责人:Denes V. Agoston
-
依托单位:
An hnRNP A-like Protein in Neural Stem Cells
-
批准号:6401171
-
项目类别:
-
资助金额:$7.41万
-
财政年份:2001
-
负责人:Denes V. Agoston
-
依托单位:
Lymphoid Transcription Factor in Striatal Development
-
批准号:6370699
-
项目类别:
-
资助金额:$7.41万
-
财政年份:2001
-
负责人:Denes V. Agoston
-
依托单位:
海外基金